MediMix Oncology
  • Home
  • Congresses
    • 2025
      • ASCO 2025
      • ASCO GI 2025
      • ENETS 2025
      • ELCC 2025
      • EADO 2025
    • 2024
      • SABCS 2024
      • ESMO 2024
      • ESMO GI 2024
      • ASCO 2024
      • JFHOD 2024
      • ASCO GU 2024
      • ESGO & SGO 2024
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
Browse Tag

in-depth

200 Articles

Improving cognitive impairment in cancer survivors

Admin
Admin
10 October 2024

MARIPOSA-2: Second interim analysis for overall survival

Admin
Admin
10 October 2024

A nurse-led clinic to deal with bowel problems in rectal cancer survivors

Admin
Admin
10 October 2024

RELATIVITY-104 study

Admin
Admin
10 October 2024

MARIPOSA study: mechanisms of acquired resistance

Admin
Admin
10 October 2024

The evolving treatment landscape for HR+/HER2- advanced breast cancer

Admin
Admin
9 October 2024

Abstract 510MO – pembro MSI-H

Admin
Admin
8 October 2024

The TREAT ctDNA study & the role of liquid biopsies in breast cancer

Admin
Admin
7 October 2024

KEYNOTE-811: final analysis for overall survival

Admin
Admin
7 October 2024

SUNLIGHT: effect of clinical prognostic factors at baseline

Admin
Admin
7 October 2024
« Previous 1 … 4 5 6 7 8 … 20 Next »

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Congresses
    • 2025
      • ASCO 2025
      • ASCO GI 2025
      • ENETS 2025
      • ELCC 2025
      • EADO 2025
    • 2024
      • SABCS 2024
      • ESMO 2024
      • ESMO GI 2024
      • ASCO 2024
      • JFHOD 2024
      • ASCO GU 2024
      • ESGO & SGO 2024
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok